|
Novo Integrated Sciences, Inc. (NVOS) DCF Valoración
US | Healthcare | Medical - Care Facilities | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Novo Integrated Sciences, Inc. (NVOS) Bundle
¡Descubra el verdadero valor de Novo Integrated Sciences, Inc. (NVOS) con nuestra calculadora DCF de grado profesional! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo los cambios afectan la valoración de Novo Integrated Sciences, Inc. (NVO), todo dentro de una sola plantilla de Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.9 | 9.3 | 11.7 | 12.6 | 13.3 | 15.2 | 17.4 | 19.9 | 22.7 | 26.0 |
| Revenue Growth, % | 0 | 18.38 | 26.14 | 7.11 | 5.75 | 14.34 | 14.34 | 14.34 | 14.34 | 14.34 |
| EBITDA | -2.8 | -2.6 | -22.5 | -5.8 | -10.1 | -8.7 | -9.9 | -11.3 | -13.0 | -14.8 |
| EBITDA, % | -35.38 | -27.75 | -191.52 | -46.52 | -75.79 | -57.09 | -57.09 | -57.09 | -57.09 | -57.09 |
| Depreciation | 2.0 | 2.4 | 3.0 | 2.3 | .0 | 2.9 | 3.3 | 3.8 | 4.3 | 4.9 |
| Depreciation, % | 25.27 | 25.44 | 25.72 | 18.32 | 0 | 18.95 | 18.95 | 18.95 | 18.95 | 18.95 |
| EBIT | -4.8 | -4.9 | -25.5 | -8.2 | -10.1 | -10.8 | -12.3 | -14.1 | -16.1 | -18.4 |
| EBIT, % | -60.65 | -53.18 | -217.24 | -64.84 | -75.79 | -70.89 | -70.89 | -70.89 | -70.89 | -70.89 |
| Total Cash | 2.1 | 8.3 | 2.2 | .4 | .8 | 4.4 | 5.0 | 5.7 | 6.5 | 7.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.0 | 2.3 | 2.1 | 1.5 | 3.2 | 3.2 | 3.6 | 4.1 | 4.7 | 5.4 |
| Account Receivables, % | 25.89 | 24.53 | 17.91 | 11.67 | 23.71 | 20.74 | 20.74 | 20.74 | 20.74 | 20.74 |
| Inventories | .0 | .3 | .9 | 1.1 | 1.0 | .8 | 1.0 | 1.1 | 1.2 | 1.4 |
| Inventories, % | 0.000012721729 | 3.65 | 7.49 | 8.81 | 7.53 | 5.49 | 5.49 | 5.49 | 5.49 | 5.49 |
| Accounts Payable | .9 | 1.4 | 1.8 | 3.5 | 3.2 | 2.9 | 3.3 | 3.8 | 4.3 | 4.9 |
| Accounts Payable, % | 11.24 | 15.58 | 15.34 | 27.95 | 24.34 | 18.89 | 18.89 | 18.89 | 18.89 | 18.89 |
| Capital Expenditure | .0 | -.3 | -.2 | .0 | .0 | -.2 | -.2 | -.2 | -.2 | -.3 |
| Capital Expenditure, % | -0.15406 | -2.75 | -1.62 | -0.39154 | -0.37026 | -1.06 | -1.06 | -1.06 | -1.06 | -1.06 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.8 | -4.9 | -25.3 | -8.1 | -10.1 | -10.7 | -12.3 | -14.0 | -16.1 | -18.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3.9 | -2.8 | -22.5 | -3.7 | -12.0 | -8.2 | -9.3 | -10.7 | -12.2 | -14.0 |
| WACC, % | 4.2 | 4.2 | 4.18 | 4.19 | 4.2 | 4.19 | 4.19 | 4.19 | 4.19 | 4.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -47.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -14 | |||||||||
| Terminal Value | -649 | |||||||||
| Present Terminal Value | -528 | |||||||||
| Enterprise Value | -576 | |||||||||
| Net Debt | 4 | |||||||||
| Equity Value | -580 | |||||||||
| Diluted Shares Outstanding, MM | 18 | |||||||||
| Equity Value Per Share | -32.16 |
What You Will Get
- Editable Forecast Inputs: Effortlessly adjust assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Novo Integrated Sciences, Inc. (NVOS) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that caters to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Financial Data: Novo Integrated Sciences' historical financial statements and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe the intrinsic value of Novo Integrated Sciences recalculating instantly.
- Intuitive Visual Displays: Dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-prepared Excel file containing Novo Integrated Sciences, Inc.'s (NVOS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly evaluate different outcomes.
- Make Decisions: Leverage the valuation results to inform your investment approach.
Why Choose Novo Integrated Sciences, Inc. (NVOS)?
- Save Time: Skip the complexities of financial modeling – our tools are ready for immediate use.
- Enhance Accuracy: Dependable data and methodologies minimize valuation errors.
- Completely Customizable: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive visuals and outputs simplify the analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize both precision and ease of use.
Who Should Use Novo Integrated Sciences, Inc. (NVOS)?
- Health Science Students: Explore innovative approaches to integrated health solutions and apply them in practical scenarios.
- Researchers: Utilize advanced models and data in studies related to integrated health sciences.
- Investors: Evaluate market trends and assess the potential of Novo Integrated Sciences, Inc. (NVOS) in your investment strategy.
- Healthcare Analysts: Enhance your analysis with a customizable model tailored for integrated health companies.
- Entrepreneurs: Understand how innovative health solutions are developed and marketed in the public sector.
What the Template Contains
- Historical Data: Includes Novo Integrated Sciences' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Novo Integrated Sciences' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Novo Integrated Sciences' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.